Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-AP5
Description: Potent and selective NMDA antagonist; less active form of DL-AP5
Chemical Name: L-(+)-2-Amino-5-phosphonopentanoic acid
Purity: ≥99% (HPLC)
Biological Activity for L-AP5
L-AP5 is an NMDA antagonist and an agonist at quisqualate-sensitized AP6 site, where it is more potent than the isomer D-AP5. L-AP5 is more potent than D-AP5 at depressing synaptic responses at amino acid-induced and synaptic excitation of cat spinal neurons.
D-isomer, DL mixture and sodium salt also available.
Technical Data for L-AP5
| M. Wt | 197.13 |
| Formula | C5H12NO5P |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 79055-67-7 |
| PubChem ID | 1617110 |
| InChI Key | VOROEQBFPPIACJ-BYPYZUCNSA-N |
| Smiles | [H][C@@](CCCP(O)(O)=O)(N)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for L-AP5
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 100 |
Preparing Stock Solutions for L-AP5
The following data is based on the product molecular weight 197.13. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 5.07 mL | 25.36 mL | 50.73 mL |
| 5 mM | 1.01 mL | 5.07 mL | 10.15 mL |
| 10 mM | 0.51 mL | 2.54 mL | 5.07 mL |
| 50 mM | 0.1 mL | 0.51 mL | 1.01 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for L-AP5
References for L-AP5
References are publications that support the biological activity of the product.
Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378 PMID: 6145492
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Schulte et al (1994) Utilization of the resolved L-isomer fo 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203 PMID: 7953634
If you know of a relevant reference for L-AP5, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: L-AP5, L-AP5 supplier, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGlu, Ionotropic, L-APV, LAPV, L_APV, LAP5, AP5, 0107, Tocris Bioscience
3 Citations for L-AP5
Citations are publications that use Tocris products. Selected citations for L-AP5 include:
Fan et al (2016) Reduced Hyperpolarization-Activated Current Contributes to Enhanced Intrinsic Excitability in Cultured Hippocampal Neurons from PrP(-/-) Mice. Front Cell Neurosci 10 74 PMID: 27047338
Kinney (2005) GAT-3 transporters regulate inhibition in the neocortex. J Neurophysiol 94 4533 PMID: 16135550
Fernández-Monreal et al (2004) Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-MthD.-aspartate receptor signaling. J Biol Chem 279 50850 PMID: 15448144
Do you know of a great paper that uses L-AP5 from Tocris? Please let us know.
Reviews for L-AP5
Average Rating: 5 (Based on 1 Review.)
Have you used L-AP5?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
AP5 decreases neuronal acitvity.
By
Luiz Alexandre Magno on 10/26/2018
Assay Type: In Vivo
Species: Mouse
Cell Line/Tissue: Brain
AP5 is an NMDA antagonist, so we have used it to block the function of neurons. Neuronal activity of animals injected with AP5 into the brain were decreased, seen as low expression of the protein CFOS.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.